AIDS diagnoses at higher CD4 counts in Australia following the introduction of highly active antiretroviral treatment

AIDS

Volumn 13, Issue 2, 1999, Pages 263-269

  Law, Matthew G ^a   De Winter, Leandra ^a   McDonald, Ann ^a   Cooper, David A ^a   Kaldor, John M ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

CD4; Combination therapy; Surveillance

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; AUSTRALIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION;

EID: 0033006142     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199902040-00015     Document Type: Article

References (16)

1. Correll PK, Law MC, McDonald AM, Cooper DA, Kaldor JM: HIV disease progression in Australia in the time of combination antiretroviral therapies. Med J Aust 1998, 169:469-472.
2. Egger M, Hirschel B, Francioli P, et al.: Impact of new antiretroviral combination therapies in HIV infected people in Switzerland: prospective multicentre study. BMJ 1997, 315:1194-1199.
3. Hogg RS, Heath KV, Yip B, et al.: Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998, 279:450-454.
4. National Centre in HIV Epidemiology and Clinical Research (editor): HIV/AIDS and related diseases in Australia: Annual Surveillance Report 1998. Sydney, Australia: NCHECR, UNSW; 1998.
5. European Centre for Epidemiological Monitoring of AIDS: HIV/AIDS surveillance in Europe: Quarterly Report no. 57, 31 March 1998.
6. Dore GJ, Li Y, Grulich AE, et al.: Declining incidence and later occurrence of Kaposi's sarcoma among persons with AIDS in Australia: the Australian AIDS cohort. AIDS 1996, 10:1401-1406.
7. Dore GJ, Hoy JF, Mallal SA, et al.: Trends in the incidence of AIDS illnesses in Australia from 1983 to 1994: the Australian AIDS Cohort. J Acquired Immune Defic Syndr Human Retrovirol 1997, 16:39-43.
8. Jacobson MA., Zegans M, Pavan PR, et al.: Cytomegalovirus after initiation of highly active antiretroviral therapy. Lancet 1997, 349:1443-1445.
9. Race EM, Adelson-Mitty J, Kriegel GR, Barlam TF, Reimann KA, Letvin NL, Japour AJ: Focal mycobacterial lymphadenitis following the initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease, Lancet 1998, 351:252-255.
10. Kelleher AD, Carr A, Zaunders J, Cooper DA: Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996, 16:321-329.
11. + T-cell receptor repertoire that are not corrected by antiretroviral or immune-based therapies. Nat Med 1997, 3:533-540.
12. Stein DS: Cytomegalovirus after initiation of highly active antiretroviral therapy [letter]. Lancet 1997, 350:588-589.
13. Kaldor J, McDonald AM, Blumer CF, et al.: The acquired immunodeficiency syndrome in Australia: incidence 1982-1991. Med J Aust 1993, 158:10-17.
14. Centers for Disease Control and Prevention: Update on acquired immunodeficiency syndrome (AIDS). MMWR 1982, 31:507-514.
15. Whyte BM, Cooper DA: The surveillance definition of the acquired immunodeficiency syndrome and the clinical classification of infection with the human immunodeficiency virus type 1. Med J Aust 1988, 149:368-373.
16. Australian National Council on AIDS: Definition of HIV infection and AIDS defining illnesses. ANCA Bulletin No. 18. Canberra; April 1994.